Lanrenet (Lanreotide)

Lanreotide mimics the natural hormone somatostatin and binds to somatostatin receptors, primarily SSTR2 and SSTR5, on target cells. This binding blocks adenylate cyclase activity, lowering cyclic AMP levels and suppressing the release of growth hormone, insulin, glucagon, and other peptide hormones involved in the listed conditions.

The specific dose and dosing interval of Lanrenet are determined by the prescribing clinician based on the patient’s condition, severity, and response to therapy. Healthcare providers tailor the regimen to achieve optimal hormone control while minimizing adverse effects.

Safety data for lanreotide in pregnancy and lactation are limited. The drug should only be used if the potential benefit to the mother outweighs any possible risk to the fetus or infant. Women who are pregnant, planning pregnancy, or breastfeeding should discuss treatment options with their healthcare professional.

To request Lanrenet, submit an enquiry on the product page at gnhindia.com, specifying the required quantity. GNH India works with hospitals, pharmacies, and procurement teams worldwide, confirming trade or institutional credentials before providing pricing, availability, shipping details (including cold‑chain where needed), and required import documentation.

Lanrenet (lanreotide) and octreotide are the two most widely used somatostatin analogues. Both bind to similar receptor subtypes, but lanreotide has a longer dosing interval, often allowing monthly administration, whereas octreotide may require more frequent dosing. Choice depends on patient preference, clinical response, and physician assessment.

Lanrenet should be stored in a refrigerator at 2‑8 °C (36‑46 °F). Keep the product in its original packaging, protect it from light, and avoid freezing or shaking the vial. If temporary storage at room temperature is unavoidable, limit exposure to less than 24 hours.

Lanrenet is given by subcutaneous injection, typically into the abdomen or thigh. The injection is performed by a trained healthcare professional or, after proper instruction, by the patient or caregiver. The injection site should be rotated to reduce local irritation.

Serious adverse events linked to Lanrenet include gallbladder disease (such as cholelithiasis), severe hyperglycemia or new‑onset diabetes, pancreatitis, and rare allergic reactions like anaphylaxis. Patients should be monitored for abdominal pain, unexplained fever, or signs of infection and report any concerns promptly.

Lanrenet is contraindicated in patients with known hypersensitivity to lanreotide or any of its excipients. Caution is advised for individuals with active gallbladder disease, severe uncontrolled diabetes, or active pancreatitis. Pregnant or nursing women should only use it when clearly indicated by a physician.